189 related articles for article (PubMed ID: 24405730)
1. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.
Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R
Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730
[TBL] [Abstract][Full Text] [Related]
2. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
3. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.
Gómez R; Simón C; Remohí J; Pellicer A
Endocrinology; 2002 Nov; 143(11):4339-48. PubMed ID: 12399430
[TBL] [Abstract][Full Text] [Related]
5. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
Saylan A; Arioz DT; Koken T; Dilek H; Saylan F; Yilmazer M
Acta Obstet Gynecol Scand; 2010 May; 89(5):692-9. PubMed ID: 20423279
[TBL] [Abstract][Full Text] [Related]
6. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
7. The effects of resveratrol on ovarian hyperstimulation syndrome in a rat model.
Ozgur S; Oktem M; Altinkaya SO; Oktem EO; Cenksoy C; Erdem O; Elbeg S; Helvaci A; Erdem A; Erdem M
Taiwan J Obstet Gynecol; 2018 Jun; 57(3):383-388. PubMed ID: 29880170
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats.
Kitajima Y; Endo T; Manase K; Nishikawa A; Shibuya M; Kudo R
Fertil Steril; 2004 Mar; 81 Suppl 1():842-9. PubMed ID: 15019818
[TBL] [Abstract][Full Text] [Related]
9. Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study.
Pala Ş; Atilgan R; Ozkan ZS; Kavak SB; Ilhan N; Akpolat N; Sapmaz E
Drug Des Devel Ther; 2015; 9():1761-6. PubMed ID: 25848212
[TBL] [Abstract][Full Text] [Related]
10. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model.
Quintana R; Kopcow L; Marconi G; Young E; Yovanovich C; Paz DA
Fertil Steril; 2008 Oct; 90(4 Suppl):1511-6. PubMed ID: 18166186
[TBL] [Abstract][Full Text] [Related]
12. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
[TBL] [Abstract][Full Text] [Related]
13. Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model.
Luo J; Qi Q; Chen Y; Wang Y; Xie Q
Reprod Biomed Online; 2021 Feb; 42(2):291-300. PubMed ID: 33249057
[TBL] [Abstract][Full Text] [Related]
14. Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model.
Engin-Ustun Y; Yılmaz S; Timur H; Ustun Y; Moraloglu O; Deveer R; Yılmaz N
Gynecol Endocrinol; 2013 Sep; 29(9):851-4. PubMed ID: 23862585
[TBL] [Abstract][Full Text] [Related]
15. In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome.
Di Pietro M; Pascuali N; Scotti L; Irusta G; Bas D; May M; Tesone M; Abramovich D; Parborell F
Mol Hum Reprod; 2017 Jun; 23(6):417-427. PubMed ID: 28379469
[TBL] [Abstract][Full Text] [Related]
16. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5.
Kitajima Y; Endo T; Nagasawa K; Manase K; Honnma H; Baba T; Hayashi T; Chiba H; Sawada N; Saito T
Endocrinology; 2006 Feb; 147(2):694-9. PubMed ID: 16269461
[TBL] [Abstract][Full Text] [Related]
17. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.
Ferrero H; García-Pascual CM; Gaytán M; Morales C; Simón C; Gaytán F; Pellicer A; Gómez R
Fertil Steril; 2014 Nov; 102(5):1468-1476.e1. PubMed ID: 25217874
[TBL] [Abstract][Full Text] [Related]
18. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
BJOG; 2014 Jun; 121(7):848-55. PubMed ID: 24621101
[TBL] [Abstract][Full Text] [Related]
19. GnRH Agonist Triggering Modulates PEDF to VEGF Ratio Inversely to hCG in Granulosa Cells.
Miller I; Chuderland D; Ron-El R; Shalgi R; Ben-Ami I
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1428-36. PubMed ID: 26308290
[TBL] [Abstract][Full Text] [Related]
20. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats.
Ishikawa K; Ohba T; Tanaka N; Iqbal M; Okamura Y; Okamura H
Endocr J; 2003 Oct; 50(5):515-25. PubMed ID: 14614207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
